Trgovina Alimera Sciences, Inc. - ALIM CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Razmik | 0.19 | ||||||||
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.024874% | ||||||||
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | 0.002651% | ||||||||
Čas nočne pristojbine | 21:00 (UTC) | ||||||||
Min. tržena količina | 1 | ||||||||
Valuta | USD | ||||||||
Kritje | 20% | ||||||||
Borza | United States of America | ||||||||
Provizija na trgovanje | 0% |
*Information provided by Capital.com
Predhodno. Zapri* | 1.72 |
Odpri* | 1.76 |
Enoletna sprememba* | -65.15% |
Dnevni razpon* | 1.74 - 2.06 |
Razpon 52 wk | 1.30-7.92 |
Povprečni obseg (10 dni) | 82.77K |
Povprečni obseg (3 meseci) | 469.73K |
Tržna kapitalizacija | 14.73M |
Razmerje P/E | -100.00K |
Število delnic v obtoku | 7.01M |
Prihodki | 54.06M |
EPS | -2.64 |
Dividenda (donosnost v %) | N/A |
Beta | 1.38 |
Datum naslednjega zaslužka | May 8, 2023 |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
---|---|---|---|---|---|---|
Mar 31, 2023 | 1.99 | 0.24 | 13.71% | 1.75 | 2.07 | 1.74 |
Mar 30, 2023 | 1.72 | -0.11 | -6.01% | 1.83 | 1.84 | 1.72 |
Mar 29, 2023 | 1.75 | -0.08 | -4.37% | 1.83 | 2.01 | 1.74 |
Mar 28, 2023 | 1.84 | 0.11 | 6.36% | 1.73 | 1.86 | 1.73 |
Mar 27, 2023 | 1.75 | 0.24 | 15.89% | 1.51 | 1.89 | 1.46 |
Mar 24, 2023 | 1.34 | 0.03 | 2.29% | 1.31 | 1.36 | 1.31 |
Mar 23, 2023 | 1.34 | -0.01 | -0.74% | 1.35 | 1.36 | 1.34 |
Mar 22, 2023 | 1.29 | -0.19 | -12.84% | 1.48 | 1.48 | 1.29 |
Mar 21, 2023 | 1.50 | -0.10 | -6.25% | 1.60 | 1.60 | 1.23 |
Mar 20, 2023 | 1.54 | -0.02 | -1.28% | 1.56 | 1.57 | 1.54 |
Mar 17, 2023 | 1.56 | 0.04 | 2.63% | 1.52 | 1.57 | 1.46 |
Mar 16, 2023 | 1.56 | 0.00 | 0.00% | 1.56 | 1.60 | 1.55 |
Mar 15, 2023 | 1.55 | -0.02 | -1.27% | 1.57 | 1.58 | 1.53 |
Mar 14, 2023 | 1.65 | -0.11 | -6.25% | 1.76 | 1.76 | 1.65 |
Mar 13, 2023 | 1.68 | 0.03 | 1.82% | 1.65 | 1.74 | 1.65 |
Mar 10, 2023 | 1.65 | -0.18 | -9.84% | 1.83 | 1.83 | 1.65 |
Mar 9, 2023 | 1.83 | -0.15 | -7.58% | 1.98 | 1.98 | 1.82 |
Mar 8, 2023 | 1.93 | 0.00 | 0.00% | 1.93 | 1.93 | 1.92 |
Mar 7, 2023 | 1.96 | -0.05 | -2.49% | 2.01 | 2.01 | 1.96 |
Mar 6, 2023 | 2.10 | 0.12 | 6.06% | 1.98 | 2.10 | 1.98 |
Alimera Sciences, Inc. Events
Čas (UTC) (UTC) | Država | Dogodek |
---|---|---|
No events scheduled |
- Letni
- Četrtletno
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Skupni prihodki | 59.029 | 50.82 | 53.943 | 46.599 | 35.912 |
Prihodki | 59.029 | 50.82 | 53.943 | 46.599 | 35.912 |
Celotni stroški prihodkov | 7.03 | 6.941 | 6.626 | 4.308 | 3.438 |
Bruto dobiček | 51.999 | 43.879 | 47.317 | 42.291 | 32.474 |
Celotni odhodki iz poslovanja | 57.438 | 51.321 | 59.217 | 58.035 | 52.364 |
Celotna prodaja/splošni/upravni stroški Odhodki | 35.843 | 32.036 | 38.958 | 38.042 | 36.249 |
Raziskave in razvoj | 13.778 | 9.668 | 10.992 | 11.274 | 12.844 |
Depreciation / Amortization | 2.579 | 2.676 | 2.641 | 2.645 | 2.684 |
Nenavadni odhodki (prihodki) | -1.792 | 0 | 1.766 | 0 | |
Prihodki iz poslovanja | 1.591 | -0.501 | -5.274 | -11.436 | -16.452 |
Prihodki (odhodki) od obresti, neto Neoperativni | -4.997 | -4.906 | -4.953 | -4.84 | -5.386 |
Čisti dobiček pred obdavčitvijo | -3.934 | -5.407 | -10.227 | -16.276 | -21.838 |
Čisti dobiček po davkih | -4.372 | -5.339 | -10.443 | -16.382 | -22.001 |
Čisti dobiček pred dodatnimi postavkami | -4.372 | -5.339 | -10.443 | -16.382 | -22.001 |
Čisti dobiček | -4.372 | -5.339 | -10.443 | -16.382 | -22.001 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -4.372 | -5.339 | -10.443 | 21.948 | -22.001 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -4.372 | -5.339 | -10.443 | 21.948 | -22.001 |
Popravljen čisti dobiček | -4.372 | -5.339 | -10.443 | 21.948 | -22.001 |
Popravljene ponderirane povprečne delnice | 6.59524 | 5.11766 | 4.7702 | 5.91587 | 66.9937 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.6629 | -1.04325 | -2.18921 | 3.71002 | -0.3284 |
Popravljen normalizirani dobiček na enoto čistega dobička | -0.83951 | -1.04325 | -2.18921 | 3.90406 | -0.3284 |
Other Operating Expenses, Total | -2.851 | ||||
Skupaj izredne postavke | 0 | 0 | 0 | ||
Total Adjustments to Net Income | 0 | 38.33 | |||
Drugo, neto | -0.528 |
Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
---|---|---|---|---|---|
Skupni prihodki | 13.598 | 14.604 | 11.898 | 13.959 | 12.153 |
Prihodki | 13.598 | 14.604 | 11.898 | 13.959 | 12.153 |
Celotni stroški prihodkov | 2.006 | 2.166 | 1.68 | 1.966 | 1.689 |
Bruto dobiček | 11.592 | 12.438 | 10.218 | 11.993 | 10.464 |
Celotni odhodki iz poslovanja | 17.009 | 16.578 | 16.045 | 16.711 | 14.175 |
Celotna prodaja/splošni/upravni stroški Odhodki | 9.856 | 9.81 | 10.093 | 10.366 | 8.559 |
Raziskave in razvoj | 4.483 | 3.932 | 3.583 | 3.72 | 3.278 |
Depreciation / Amortization | 0.664 | 0.67 | 0.689 | 0.659 | 0.649 |
Prihodki iz poslovanja | -3.411 | -1.974 | -4.147 | -2.752 | -2.022 |
Prihodki (odhodki) od obresti, neto Neoperativni | -1.567 | -1.345 | -1.256 | -1.27 | -1.218 |
Čisti dobiček pred obdavčitvijo | -5.245 | -3.098 | -5.955 | -4.139 | -4.352 |
Čisti dobiček po davkih | -5.257 | -3.115 | -5.955 | -4.106 | -4.183 |
Čisti dobiček pred dodatnimi postavkami | -5.257 | -3.115 | -5.955 | -4.106 | -4.183 |
Čisti dobiček | -5.257 | -3.115 | -5.955 | -4.106 | -4.183 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -5.257 | -3.115 | -5.955 | -4.106 | -4.183 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -5.257 | -3.115 | -5.955 | -4.106 | -4.183 |
Popravljen čisti dobiček | -5.257 | -3.115 | -5.955 | -4.106 | -4.183 |
Popravljene ponderirane povprečne delnice | 6.99658 | 6.99971 | 6.99074 | 6.93809 | 6.92417 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.75137 | -0.44502 | -0.85184 | -0.59181 | -0.60412 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Popravljen normalizirani dobiček na enoto čistega dobička | -0.75137 | -0.44502 | -0.85184 | -0.59181 | -0.60412 |
Nenavadni odhodki (prihodki) | 0 | 0 | 0 | 0 | |
Drugo, neto | -0.267 | 0.221 | -0.552 | -0.117 | -1.112 |
- Letni
- Četrtletno
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 42.16 | 34.906 | 32.745 | 34.848 | 39.322 |
Denarna sredstva in kratkoročne naložbe | 16.51 | 11.208 | 9.426 | 13.043 | 24.067 |
Denarna sredstva in ustrezniki | 16.51 | 11.208 | 9.426 | 13.043 | 24.067 |
Celotne terjatve, neto | 19.128 | 17.2 | 19.331 | 17.259 | 11.435 |
Accounts Receivable - Trade, Net | 19.128 | 17.2 | 19.331 | 17.259 | 11.435 |
Total Inventory | 2.679 | 2.746 | 1.39 | 2.405 | 1.508 |
Prepaid Expenses | 3.809 | 3.718 | 2.565 | 2.109 | 2.278 |
Other Current Assets, Total | 0.034 | 0.034 | 0.033 | 0.032 | 0.034 |
Total Assets | 58.52 | 50.855 | 50.309 | 54.108 | 59.924 |
Property/Plant/Equipment, Total - Net | 4.493 | 2.358 | 2.047 | 1.355 | 1.41 |
Property/Plant/Equipment, Total - Gross | 7.923 | 6.305 | 5.858 | 4.967 | 4.611 |
Accumulated Depreciation, Total | -3.43 | -3.947 | -3.881 | -3.612 | -3.201 |
Intangibles, Net | 10.897 | 12.838 | 14.783 | 16.723 | 18.664 |
Other Long Term Assets, Total | 0.137 | 0.753 | 0.734 | 1.182 | 0.528 |
Total Current Liabilities | 12.592 | 12.348 | 12.048 | 10.234 | 9.671 |
Accounts Payable | 8.706 | 7.461 | 7.077 | 6.355 | 5.905 |
Accrued Expenses | 3.617 | 3.197 | 4.716 | 3.643 | 3.582 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.269 | 1.69 | 0.255 | 0.236 | 0.184 |
Other Current Liabilities, Total | 0 | ||||
Total Liabilities | 61.125 | 58.833 | 54.754 | 51.386 | 45.005 |
Total Long Term Debt | 43.08 | 42.922 | 38.752 | 38.178 | 34.568 |
Long Term Debt | 43.08 | 42.408 | 38.658 | 37.873 | 34.365 |
Capital Lease Obligations | 0.514 | 0.094 | 0.305 | 0.203 | |
Other Liabilities, Total | 5.453 | 3.563 | 3.954 | 2.974 | 0.766 |
Total Equity | -2.605 | -7.978 | -4.445 | 2.722 | 14.919 |
Preferred Stock - Non Redeemable, Net | 19.227 | 19.227 | 30.344 | 30.344 | 68.795 |
Common Stock | 0.069 | 0.057 | 0.05 | 0.701 | 0.691 |
Additional Paid-In Capital | 377.229 | 365.83 | 350.117 | 346.108 | 341.622 |
Retained Earnings (Accumulated Deficit) | -397.281 | -392.539 | -383.863 | -373.42 | -395.368 |
Other Equity, Total | -1.849 | -0.553 | -1.093 | -1.011 | -0.821 |
Total Liabilities & Shareholders’ Equity | 58.52 | 50.855 | 50.309 | 54.108 | 59.924 |
Total Common Shares Outstanding | 6.93515 | 5.71937 | 4.96595 | 4.67193 | 4.60976 |
Total Preferred Shares Outstanding | 0.6 | 0.6 | 0.61015 | 0.61015 | 0.60842 |
Long Term Investments | 0.833 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 34.753 | 42.16 | 43.633 | 45.237 | 30.33 |
Denarna sredstva in kratkoročne naložbe | 9.946 | 16.51 | 21.524 | 24.78 | 8.266 |
Denarna sredstva in ustrezniki | 9.946 | 16.51 | 21.524 | 24.78 | 8.266 |
Celotne terjatve, neto | 18.776 | 19.128 | 16.21 | 15.086 | 15.702 |
Accounts Receivable - Trade, Net | 18.776 | 19.128 | 16.21 | 15.086 | 15.702 |
Total Inventory | 2.452 | 2.679 | 2.301 | 2.307 | 2.591 |
Prepaid Expenses | 3.546 | 3.809 | 3.564 | 3.029 | 3.736 |
Other Current Assets, Total | 0.033 | 0.034 | 0.034 | 0.035 | 0.035 |
Total Assets | 49.931 | 58.52 | 60.065 | 62.102 | 45.587 |
Property/Plant/Equipment, Total - Net | 4.343 | 4.493 | 3.383 | 2.199 | 2.178 |
Intangibles, Net | 10.419 | 10.897 | 11.386 | 11.875 | 12.359 |
Other Long Term Assets, Total | 0.134 | 0.137 | 0.712 | 0.729 | 0.72 |
Total Current Liabilities | 17.006 | 12.592 | 11.399 | 10.308 | 11.209 |
Accounts Payable | 6.604 | 8.706 | 7.437 | 7.083 | 6.343 |
Accrued Expenses | 3.046 | 3.617 | 3.673 | 2.924 | 2.873 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 7.356 | 0.269 | 0.289 | 0.301 | 1.993 |
Total Liabilities | 58.534 | 61.125 | 58.563 | 56.211 | 57.547 |
Total Long Term Debt | 36.245 | 43.08 | 42.838 | 42.595 | 42.803 |
Long Term Debt | 36.245 | 43.08 | 42.838 | 42.595 | 42.352 |
Capital Lease Obligations | 0.451 | ||||
Other Liabilities, Total | 5.283 | 5.453 | 4.326 | 3.308 | 3.535 |
Total Equity | -8.603 | -2.605 | 1.502 | 5.891 | -11.96 |
Preferred Stock - Non Redeemable, Net | 19.227 | 19.227 | 19.227 | 19.227 | 19.227 |
Common Stock | 0.07 | 0.069 | 0.069 | 0.069 | 0.058 |
Additional Paid-In Capital | 377.541 | 377.229 | 376.579 | 376.334 | 366.092 |
Retained Earnings (Accumulated Deficit) | -403.236 | -397.281 | -392.805 | -388.622 | -396.187 |
Other Equity, Total | -2.205 | -1.849 | -1.568 | -1.117 | -1.15 |
Total Liabilities & Shareholders’ Equity | 49.931 | 58.52 | 60.065 | 62.102 | 45.587 |
Total Common Shares Outstanding | 6.99265 | 6.93515 | 6.92717 | 6.92417 | 5.75349 |
Total Preferred Shares Outstanding | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 |
Long Term Investments | 0.282 | 0.833 | 0.951 | 2.062 | |
Other Current Liabilities, Total | 0 |
- Letni
- Četrtletno
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Čisti prihodki/začetna postavka | -4.372 | -5.339 | -10.443 | -16.382 | -22.001 |
Denarna sredstva iz poslovanja | -3.224 | -2.193 | -4.152 | -11.553 | -12.874 |
Denarna sredstva iz poslovanja | 2.579 | 2.676 | 2.641 | 2.645 | 2.684 |
Deferred Taxes | 0.61 | 0.031 | 0.454 | -0.653 | -0.092 |
Nedenarne postavke | -0.692 | 1.829 | 3.377 | 7.084 | 6.238 |
Cash Taxes Paid | 0.112 | 0.11 | 0.239 | 0.239 | 0.074 |
Denarna sredstva Plačane obresti | 4.302 | 4.556 | 4.419 | 3.571 | 4.117 |
Spremembe v obratnem kapitalu | -1.349 | -1.39 | -0.181 | -4.247 | 0.297 |
Denarna sredstva pri naložbenju | -0.621 | -0.62 | -0.174 | -0.175 | -0.238 |
Kapitalski izdatki | -0.621 | -0.62 | -0.174 | -0.175 | -0.238 |
Denarna sredstva pri financiranju | 9.823 | 3.882 | 0.869 | 0.95 | 5.723 |
Postavke denarnega toka pri financiranju | 0 | -0.019 | -2.227 | -3.808 | 0.003 |
Izdaja (odplačilo) delnic, neto | 10.044 | 0.049 | 0.902 | 0.085 | 5.902 |
Izdaja (odplačilo) dolga, neto | -0.221 | 3.852 | 2.194 | 4.673 | -0.182 |
Učinki deviznih tečajev | -0.676 | 0.714 | -0.159 | -0.248 | 0.477 |
Neto sprememba denarnih sredstev | 5.302 | 1.783 | -3.616 | -11.026 | -6.912 |
Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -14.327 | -9.07 | -5.955 | -4.372 | -0.266 |
Cash From Operating Activities | -9.724 | -7.811 | -6.213 | -3.224 | 1.459 |
Cash From Operating Activities | 2.023 | 1.359 | 0.689 | 2.579 | 1.92 |
Non-Cash Items | 2.095 | 1.318 | 1.027 | -0.692 | -1.197 |
Cash Taxes Paid | 0.224 | 0.182 | 0.018 | 0.112 | 0.047 |
Cash Interest Paid | 3.253 | 2.145 | 1.061 | 4.302 | 3.23 |
Changes in Working Capital | 0.485 | -1.418 | -1.974 | -1.349 | 1.002 |
Cash From Investing Activities | -0.171 | -0.041 | -0.149 | -0.621 | -0.5 |
Capital Expenditures | -0.171 | -0.041 | -0.149 | -0.621 | -0.5 |
Cash From Financing Activities | -0.109 | -0.164 | -0.062 | 9.823 | 9.842 |
Financing Cash Flow Items | 0 | 0 | |||
Issuance (Retirement) of Debt, Net | -0.164 | -0.204 | -0.062 | -0.221 | -0.16 |
Foreign Exchange Effects | -0.998 | -0.638 | -0.141 | -0.676 | -0.485 |
Net Change in Cash | -11.002 | -8.654 | -6.565 | 5.302 | 10.316 |
Issuance (Retirement) of Stock, Net | 0.055 | 0.04 | 10.044 | 10.002 | |
Deferred Taxes | 0.61 |
Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
---|---|---|---|---|---|---|
Ocumension Therapeutics | Corporation | 16.3366 | 1144945 | 0 | 2022-05-17 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 9.429 | 660832 | -3300 | 2022-12-31 | MED |
Caligan Partners, LP | Hedge Fund | 6.8314 | 478777 | 67250 | 2022-12-31 | MED |
Velan Capital Investment Management LP | Investment Advisor/Hedge Fund | 3.6777 | 257753 | 30151 | 2022-12-31 | MED |
HOOPP Investment Management | Pension Fund | 3.5671 | 250000 | 0 | 2022-12-31 | HIGH |
Palo Alto Investors LP | Hedge Fund | 2.8668 | 200919 | 0 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.1206 | 148624 | 58 | 2022-12-31 | LOW |
Eiswirth (Richard S Jr) | Individual Investor | 1.9408 | 136018 | 500 | 2022-10-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 1.4624 | 102494 | -10200 | 2022-12-31 | HIGH |
Holland (David R) | Individual Investor | 0.5762 | 40380 | 500 | 2022-10-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5459 | 38262 | -58 | 2022-12-31 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.4819 | 33775 | 33775 | 2022-12-31 | MED |
Jones (John Philip) | Individual Investor | 0.4592 | 32186 | 372 | 2022-10-31 | LOW |
Ashman Philip | Individual Investor | 0.4325 | 30315 | -2889 | 2023-02-03 | LOW |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.2788 | 19542 | 0 | 2022-12-31 | MED |
Bridgeway Capital Management, LLC | Investment Advisor | 0.2611 | 18300 | 0 | 2022-12-31 | LOW |
Perritt Capital Management, Inc. | Investment Advisor | 0.2568 | 18000 | 0 | 2022-12-31 | LOW |
Skibsted (Russell L) | Individual Investor | 0.2497 | 17500 | 17500 | 2023-01-09 | |
Largent (James R.) | Individual Investor | 0.1855 | 13000 | 0 | 2022-05-17 | |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.1787 | 12524 | 292 | 2022-12-31 | LOW |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group500K+
Borzni posredniki
92K+
Aktivne stranke mesečno
$53M+
Mesečni obseg naložb
$30M+
Dvigi vsak mesec
Kalkulator trgovanja
Izračunajte svoj hipotetični P&L, če bi trgovino s CFD odprli na določen datum (izberite datum) in jo zaprli na drug datum (izberite datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Alimera Sciences, Inc. Company profile
O družbi Alimera Sciences, Inc.
Alimera Sciences, Inc. je farmacevtsko podjetje. Družba se ukvarja s komercializacijo in razvojem oftalmoloških zdravil na recept. Osredotoča se na bolezni, ki prizadenejo zadnjo stran očesa ali mrežnico. Družbeni komercialni izdelek ILUVIEN je intravitrealni vsadek, s katerim se bolniki zdravijo tako, da se v oko do 36 mesecev neprekinjeno dovaja mikrodoza nelastniškega kortikosteroida fluocinolon acetonida (FAc). Podjetje se ukvarja z razvojem za zdravljenje diabetičnega makularnega edema (DME). DME je bolezen mrežnice, ki prizadene posameznike s sladkorno boleznijo in lahko povzroči hudo izgubo vida in slepoto. Zdravilo ILUVIEN se lahko uporablja tudi za preprečevanje ponovitve bolezni pri ponavljajočem se nenalezljivem uveitisu, ki prizadene zadnji segment očesa (NIU-PS). Družba ILUVIEN neposredno komercialno trži v Združenih državah Amerike, Nemčiji, Združenem kraljestvu, na Portugalskem in Irskem.
Industry: | Biopharmaceuticals |
Ste 290
6120 Windward Parkway
ALPHARETTA
GEORGIA 30005
US
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 500.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com